VINGIANI, ANDREA
 Distribuzione geografica
Continente #
EU - Europa 4.595
NA - Nord America 1.929
AS - Asia 1.332
SA - Sud America 39
OC - Oceania 36
AF - Africa 31
Continente sconosciuto - Info sul continente non disponibili 3
Totale 7.965
Nazione #
DE - Germania 2.395
US - Stati Uniti d'America 1.846
GB - Regno Unito 712
IT - Italia 681
CN - Cina 634
SE - Svezia 207
IN - India 192
SG - Singapore 95
IE - Irlanda 90
FR - Francia 86
JP - Giappone 76
TR - Turchia 68
CA - Canada 64
HK - Hong Kong 63
ID - Indonesia 58
ES - Italia 57
BE - Belgio 56
DK - Danimarca 51
FI - Finlandia 44
KR - Corea 43
NL - Olanda 34
AU - Australia 31
CH - Svizzera 30
NO - Norvegia 24
PL - Polonia 22
VN - Vietnam 22
PH - Filippine 21
GR - Grecia 17
AT - Austria 16
PT - Portogallo 15
UA - Ucraina 13
BR - Brasile 12
MX - Messico 11
RU - Federazione Russa 11
TW - Taiwan 10
IL - Israele 9
IR - Iran 9
RO - Romania 9
CZ - Repubblica Ceca 7
EG - Egitto 7
TH - Thailandia 7
AR - Argentina 6
PE - Perù 6
CL - Cile 5
CO - Colombia 5
LT - Lituania 5
NZ - Nuova Zelanda 5
SC - Seychelles 5
UG - Uganda 5
ZA - Sudafrica 5
KE - Kenya 4
MO - Macao, regione amministrativa speciale della Cina 4
QA - Qatar 4
VE - Venezuela 4
CU - Cuba 3
CY - Cipro 3
EU - Europa 3
RS - Serbia 3
BA - Bosnia-Erzegovina 2
CR - Costa Rica 2
HU - Ungheria 2
JO - Giordania 2
PK - Pakistan 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AW - Aruba 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BG - Bulgaria 1
EC - Ecuador 1
EE - Estonia 1
GH - Ghana 1
GT - Guatemala 1
HR - Croazia 1
IQ - Iraq 1
IS - Islanda 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LY - Libia 1
MA - Marocco 1
MY - Malesia 1
NI - Nicaragua 1
RE - Reunion 1
TN - Tunisia 1
Totale 7.965
Città #
Frankfurt am Main 2.162
Southend 608
Milan 267
Chandler 221
Seattle 178
Ashburn 154
Wilmington 99
Beijing 92
Dublin 90
Fairfield 88
Princeton 74
Dearborn 62
Bengaluru 59
Houston 59
Ann Arbor 58
Shanghai 56
Singapore 48
Istanbul 45
Cambridge 41
Jakarta 38
Grafing 37
Woodbridge 36
Hong Kong 34
Guangzhou 33
New York 33
Hyderabad 31
Helsinki 30
Redwood City 30
Des Moines 29
Shenyang 29
Hanover 28
Nanjing 28
Brussels 27
Rome 26
Toronto 25
London 24
Phoenix 23
Berlin 22
Jinan 22
San Diego 22
Hangzhou 18
Seoul 18
Boardman 16
Fremont 16
Nuremberg 16
Eitensheim 15
Falls Church 14
Genoa 14
Pune 14
Madrid 13
Tokyo 13
Sunnyvale 12
Turin 12
Zhengzhou 12
Amsterdam 11
Tianjin 11
Central 10
Monza 10
Oslo 10
Ottawa 10
Redmond 10
Boston 9
Central District 9
Chongqing 9
Taipei 9
Upper Marlboro 9
Ankara 8
Barcelona 8
Chicago 8
Dallas 8
Indianapolis 8
Naples 8
San Giuliano Milanese 8
Baltimore 7
Hebei 7
Los Angeles 7
Montreal 7
Montréal 7
Philadelphia 7
Rho 7
Sydney 7
Washington 7
Birmingham 6
Bytom 6
Copenhagen 6
Delhi 6
Florence 6
Haikou 6
Hefei 6
Lisbon 6
Molenbeek-Saint-Jean 6
Oxford 6
Palermo 6
Paris 6
Pittsburgh 6
Rochester 6
Silver Spring 6
Venice 6
Wuhan 6
Xian 6
Totale 5.615
Nome #
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors 691
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer 689
Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative 323
Transplantation of autologous extracellular vesicles for cancer-specific targeting 257
Cancer-derived EVs show tropism for tissues at early stage of neoplastic transformation 239
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials 229
Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence 198
A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer 182
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research 172
Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma 168
The Stearoyl-CoA desaturase1 (SCD) in Drosophila is necessary for Myc induced autophagy, a potential new link to tumor growth 158
Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison 140
Ductal carcinoma in situ and intraoperative partial breast irradiation: Who are the best candidates? Long-term outcome of a single institution series 138
Effect of metformin on breast ductal carcinoma in situ proliferation in a randomized presurgical trial 134
Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients 126
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple negative breast cancer patients after neo-adjuvant chemotherapy 123
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer 117
The clinical relevance of micropapillary carcinoma of the breast : a case-control study 116
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors : a Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group : Part 1 : Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research 114
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00 111
Retroperitoneal pararenal isolated neuro fibroma: report of a case and review of literature 109
Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma 109
Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer 107
Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast 106
Oncological Outcomes of Nipple-Sparing Mastectomy : a Single-Center Experience of 1989 Patients 100
Towards mm-wave spectroscopy for dielectric characterization of breast surgical margins 94
Macrophage morphology and distribution are strong predictors of prognosis in resected colorectal liver metastases: results from an external retrospective observational study 93
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 93
Correlation between radiological and biological features and clinical outcomes in early prostate cancer: an exploratory subgroup analysis 92
Pulmonary squamous cell carcinoma with lepidic growth pattern : new insights into lung cancer classification 80
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer 76
Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer 76
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group 74
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy 74
Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab 73
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients 72
Malignant salivary gland tumours in families with breast cancer susceptibility 71
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin 70
The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast 69
Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial 69
Clinical outcomes and radio-biological features correlation in early pca: An exploratory analysis 66
Fatty acid uptake as a potentially new resistance mechanism to anti-HER2 treatments in HER2-positive breast cancer 66
Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model 65
MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers 64
Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy 63
Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer 62
Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma 61
Targeted-gene sequencing to catch triple negative breast cancer heterogeneity before and after neoadjuvant chemotherapy 61
12P The RODILIA pilot study for molecular screening of patients with metaplastic breast cancer 60
Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world 57
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer 57
Contrast-enhanced mammography in the evaluation of breast calcifications: preliminary experience 57
Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer 55
Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group 55
End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO 54
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC) 53
Detection of genomically aberrant cells within circulating tumor microemboli (CTMs) isolated from early-stage breast cancer patients 53
Clinical performance of contrast-enhanced spectral mammography in pre-surgical evaluation of breast malignant lesions in dense breasts: a single center study 51
Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer 51
Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples 51
Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer 50
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications 50
Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer 49
Analysis of Efficacy and Accuracy of 2 Vacuum-Assisted Breast Biopsy Devices: Mammotome and Elite 49
Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)epositive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy 48
Innate immunity in colorectal liver metastases: macrophage morphology and distribution are strong predictors of prognosis: An external validation 48
Mammographic density to predict response to neoadjuvant systemic breast cancer therapy 47
The impact of COVID-19 on diagnosis of recurrent breast cancer 46
A single-arm, open-label, multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck 45
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 45
ROS1 Gene Fusion in Advanced Lung Cancer in Women : A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm 44
Primary tumor somatic mutations in the blood of women with ductal carcinoma in situ of the breast 43
Solitary thyroid metastasis from colon cancer: A rare case report 43
Mammographic density to predict response to neoadjuvant chemotherapy for breast cancer 43
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer 42
Enhancers mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer 41
Salivary gland choristoma in large bowel 41
Ultra-deep multigene profiling of matched primary and metastatic hormone receptor positive breast cancer patients relapsed after adjuvant endocrine treatment reveals novel aberrations in the estrogen receptor pathway 41
Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC) 39
First report of AURORA, the breast international group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts) 38
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers 36
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/ metastatic head and neck squamous cell carcinoma treated with nivolumab 28
Multidisciplinary management of pregnancy-associated and early post-partum head and neck cancer patients 22
Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy 11
The pathology report 7
Tumor infiltrating lymphocytes in early breast cancer 5
null 4
null 3
null 3
Abstract HER2-02: HER2-02 HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy 1
Totale 8.306
Categoria #
all - tutte 21.863
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.863


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201919 0 0 0 0 0 0 0 0 0 0 0 19
2019/2020543 64 10 4 43 52 64 58 33 100 61 35 19
2020/2021789 60 47 22 27 73 79 77 70 127 97 44 66
2021/2022990 84 73 51 57 78 39 50 75 172 113 65 133
2022/20231.815 160 122 149 194 228 370 116 77 110 58 164 67
2023/20243.351 91 99 86 94 250 226 532 451 238 468 542 274
Totale 8.306